凝血酶的特异性抑制剂的实例包括水蛭素、比伐卢定(Angiomax⑧)、阿加曲班、希美加群(Exanta⑧,参见下文结构)、达比加群(参见下文结构)、AZD0837(处在临床试验研究中,AControlled,Randomized,Parallel,Multi-CentreFeasibilityStudyoftheOralDirectThrombinInhibitor,AZD0837,GivenasERFormulation,inthePreventionofStrokeand...
contrast, most PD studies have focused on clinical observations, and few preclinical findings have been reported. Some cases have suggested that the combination of the two types of drugs would alter the antiplatelet efficacy and adverse effects. Studies on PK, however, have shown significant or sli...
Thus, careful consideration of the benefit–risk ratio for each patient is needed to optimize the anti-platelet therapy in terms of drugs to use and length of treatment on an individual level. In addition to these already launched P2Y12 receptor antagonists, there are two other non-...
Inhibitor Monotherapy versus 12 Months’ Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials Abstract Introduction An increased incidence of stent thrombosis after implantation of first-generation drug-eluting stents led to a ...
Also, a crossover study including 56 patients with type 2 diabetes mellitus found plasma levels of miR-197 and miR-223 alongside miR-191 and miR-24 to be lower in diabetic patients on the P2Y12 inhibitor prasugrel, compared with aspirin [26]. We have previously reported a decrease of ...